Mizuho's initiation of coverage on Herbalife with a Neutral rating suggests that the stock is fairly valued at its current price. The announcement of a $13 price target indicates that Mizuho does not expect significant price movement in the short term. This news is important for investors as it provides an expert opinion on the stock's valuation, but the neutral rating suggests a limited impact on the stock price in the short term.